ADA Meeting's Around The Corner: Five Things To Watch For
Executive Summary
Among other debates at the American Diabetes Association annual meeting, clinicians will discuss the future of cardiovascular outcomes studies for diabetes drugs – whether they should maintain course or are due for an overhaul.
You may also be interested in...
Novo Nordisk's Oral Semaglutide Succeeds In First Phase III, But Prompts Questions
In PIONEER 1, weight loss results for the oral version of the GLP-1 agonist were somewhat disappointing and lack of detail in the top-line release prompts concerns about compliance.
Novo Nordisk Plans Value-based Contracts For GLP-1 Agonist Ozempic
Company aims to shift gradually away from once-daily GLP-1 Victoza (liraglutide) toward once-weekly Ozempic (semaglutide).
Biocon’s Oral Insulin Gains Momentum With JDRF Backing
Biocon’s oral insulin program has received a boost with the US-based JDRF supporting plans to progress its drug candidate in type 1 diabetes. While the pullback of players like Novo Nordisk underscores the potential risks in the oral insulin space, JDRF says early results of Biocon’s candidate “warrant support” for further studies.